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Introduction
Schizophrenia (MIM 181500) is a severe and common
psychiatric disorder afflicting 1% of the world popu-
lation. The disease is characterized by psychotic symp-
toms and by cognitive, affective, and psychosocial im-
pairment. As a leading cause of psychiatric admissions,
schizophrenia accounts for a considerable portion of
health-care expenditures and is viewed as a major public
health concern.
Despite extensive research, our knowledge of the
structural or functional pathology of schizophrenia is
limited. The only etiological factor with a reasonably
firm foundation is inheritance, as evidenced by family,
twin, and adoption studies that point to substantial her-
itability (Gottesman and Shields 1982; Gottesman
1991; Kendler and Diehl 1993).
In the premolecular era, attempts to discern the un-
derlying genetic mechanism consisted of (1) segregation
analysis, testing the fit of observed familial patterns to
specific genetic formulations (e.g., single–major-locus,
oligogenic, and multifactorial-polygenic models); (2)
searching for genetic susceptibility traits, also known as
“biological markers,” that segregate with the disorder
in families (e.g., neurotransmitter enzymes, receptor
proteins, or metabolites; attentional and electroenceph-
alographic measures; and indices based on brain im-
aging); and (3) linkage studies that used classical gene
markers (e.g., leukocyte antigens, blood groups, or se-
rum proteins). However, in spite of numerous studies,
the genetic underpinnings of schizophrenia remain elu-
sive. The disorder, which is confounded by a host of
factors (e.g., phenotypic diversity, etiologic heteroge-
neity, incomplete penetrance, unknown mode of inher-
itance, uncertainty about the number of loci involved
and about their interactions, and the existence of non-
genetic cases or phenocopies), was consigned to a com-
plex multifactorial etiology, with no firmly established
Received December 4, 2000; accepted for publication December 6,
2000; electronically published January 17, 2001.
Address for correspondence and reprints: Dr. Miron Baron, De-
partment of Psychiatry, Columbia University, 1051 Riverside Drive,
Unit 6, New York, NY 10032. E-mail: mb17@columbia.edu
 2001 by The American Society of Human Genetics. All rights reserved.
0002-9297/2001/6802-0002$02.00
biological correlates (Baron 1986a and 1986b; Risch
1990b; Kendler and Diehl 1993). A single major locus
is unlikely as a common mode of inheritance. Oligo-
genic or polygenic models are plausible alternatives.
The advent of molecular genetics was a turning point
in schizophrenia research, enabling the systematic ap-
plication of both reverse genetics (studying random,
anonymous DNA markers spanning the genome) and
forward-genetics (testing candidate-gene polymor-
phisms with presumed functional relevance for the dis-
ease) (Martin 1987; Baron and Rainer 1988; Owen and
Craddock 1996). In this article I review molecular ge-
netic findings about schizophrenia, with an eye toward
methodological issues and future research.
Findings
The search for schizophrenia genes appeared to be off
to an auspicious start when Sherrington et al. (1988)
reported strong statistical evidence of linkage to DNA
markers on chromosome 5q11-13, in British and Ice-
landic pedigrees (a LOD score of 6.49, under a dominant
model of inheritance and a broad disease definition).
However, failure to replicate this finding in independent
samples, coupled with heightened awareness of pheno-
typic and genetic complexities, dimmed the initial op-
timism, and the disease was dubbed a “graveyard for
molecular geneticists” (Owen 1992). The initial finding
was eventually retracted after a more extensive analysis
of the original sample and consideration of additional
data (Kalsi et al. 1999).
Conflicting results may arise because of complex in-
heritance that leads to reduced power and to difficulties
in distinguishing a true-positive result from a false-pos-
itive one (type 1 error) and in distinguishing a true-
negative result from a false-negative one (type 2 error).
But a host of other factors must be considered, includ-
ing diagnostic uncertainties, variability among studies
in methods of data collection and interpretation, selec-
tion bias, incomplete genotypic information, and sta-
tistical artifacts. Several methodological advances have
occurred to counter these problems (Baron 1990, 1995;
Baron et al. 1990; Risch 1990a; Pauls 1993; Spence et
al. 1993; Cloninger 1994; Lander and Kruglyak 1995;
Owen and Craddock 1996). These include operation-
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alized diagnostic constructs and practices, which en-
hance diagnostic reliability and consensus among re-
searchers; focus on conservative definitions of the
phenotype, to diminish phenotypic ambiguities; main-
tainenance of scrupulous “blindness” between those
conducting diagnostic procedures and those performing
genotyping, to avert systematic errors; systematic as-
certainment of subjects and pedigrees, to counter selec-
tion bias; power simulations, to assess the suitability of
clinical samples; a range of analytical models for gene
detection; dense genetic maps that allow genomewide
searches; and statistical guidelines for the prudent in-
terpretation of results (e.g., adjusting for multiple test-
ing and performing simulations to determine power and
levels of significance).
Coupled with advances in other complex disorders
(e.g., Alzheimer disease, diabetes, and certain types of
cancer), the improved methodology has rekindled in-
terest in the genetics of schizophrenia. A new harvest
of findings has been reported, including results of ge-
nome searches using linkage mapping and results of
studies of candidate genes and chromosomal aberra-
tions. Findings are compiled in the World Congress on
Psychiatric Genetics chromosome workshops (Crow
and DeLisi 1998; DeLisi and Crow 1998; DeLisi et al.
1999). To narrow the scope of this review, I focus on
findings that seem promising by virtue of statistical sig-
nificance or some consistency across studies. It must be
stressed, however, that criteria for significance in the
genetic analysis of complex disease are not well estab-
lished and that positive results are often followed by
attempts at replication that yield negative or equivocal
findings.
Linkage Studies
Linkage studies are the mainstay of gene-finding strat-
egies in psychiatric genetics. Significant or suggestive ev-
idence of linkage (Lander and Kruglyak 1995) (see the
“Linkage Methods” subsection, below) has been re-
ported in several chromosomal regions: 1q21-22, 1q32-
41, 4q31, 5p13-14, 5q22-31, 6p22-24, 6q21-22, 8p21-
22, 9q21-22, 10p11-15, 13q14-32, 15q15, 22q11-13,
and Xp11. There are preliminary results from other ge-
nome scans or candidate regions, but evaluation must
await the full published reports.
Chromosome 1q21-22.—Brzustowicz et al. (2000) re-
ported a genomewide scan in 22 Canadian pedigrees,
which showed pronounced linkage to 1q21-22. A max-
imum heterogeneity LOD score of 6.50 was found be-
tween markers D1S1653 and D1S1679, under a reces-
sive model and a narrow disease definition, and ∼75%
of the families were linked to this locus. The strength of
the evidence is unusual for a complex disorder such as
schizophrenia, especially given an outbred population
and a relatively small sample. The authors attributed
their apparent success to the dense pedigrees selected for
study and to a fortuitous sample variation. Marginal
support for linkage to 1q22-23 was noted in an earlier
study (Shaw et al. 1998). A potassium-channel gene
(hKCa3/KCNN3) mapped to 1q21 was reportedly as-
sociated with schizophrenia in one study (Dror et al.
1999), although linkage analysis in an independent sam-
ple found no evidence for the involvement of hKCa3/
KCNN3 in the disease (Austin et al. 1999).
Chromosome 1q32-41.—Hovatta et al. (1999) re-
ported a three-stage genomewide scan in 69 families
from a Finnish population isolate. They observed amax-
imum LOD score of 3.82 at marker D1S2891, under a
dominant model and a narrow disease definition, with
no evidence of locus heterogeneity. A putative haplotype,
which might narrow the chromosomal region impli-
cated, was observed in some core families.
Chromosome 4q31.—Hovatta et al. (1999) also ob-
served a maximum LOD score of 2.74 at marker
D4S1586, under a dominant model and a narrow di-
agnostic model. Positive LOD scores occurred on a fairly
large region, and the evidence was supported by affected
sib-pair analysis with the same marker (LOD score of
2.09; ).Pp .00097
Chromosome 5p13-14.—Silverman et al. (1996) re-
ported a maximum LOD score of 4.37 at locus D5S111,
under dominant inheritance and a broad disease defi-
nition (including putative schizophrenia-related pheno-
types), in one large Puerto Rican pedigree. However, the
LOD score was not robust to sensitivity analysis (testing
the impact of diagnostic misclassifications on the evi-
dence for linkage), and 23 other families examined con-
currently showed no evidence of linkage to this region,
suggesting that the putative disease gene is rare.
Chromosome 5q22-31.—After a genome scan of 265
Irish pedigrees, Straub et al. (1997) reported amaximum
heterogeneity LOD score of 3.35 ( ) at markerPp .0002
D5S804, under a recessive genetic model and a narrow
diagnostic model, and ∼10%–25% of the families linked
to this locus. D5S804 is mapped to 5q22, but positive
LOD scores were in evidence across the entire 5q22-31
region. Schwab et al. (1997) reported additional sup-
port, albeit at a lower level of significance, for linkage
to this region (marker D5S399 at 5q31), in German and
Israeli families.
Chromosome 6p22-24.—Straub et al. (1995), follow-
ing up on a report on a subset of the data in the same
German and Israeli families (Wang et al. 1995), studied
265 Irish families for linkage to 6p22-24. They reported
a maximum LOD score of 3.51 ( ) at markerPp .0002
D6S296, under an additive genetic model and a broad
definition of schizophrenia (including putative schizo-
phrenia-related disorders). An estimated 15%–30% of
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the families were presumed linked to this region. The
evidence of linkage declined substantially when the nar-
row disease definition was used. Additional, support for
linkage to this region was reported by Schwab et al.
(1995 and 2000) in German and Israeli families, by
Moises et al. (1995) in 65 European, Canadian, U.S.,
and Taiwanese families, and by Antonarakis et al. (1995)
in 57 U.S. families.
Chromosome 6q21-22.—Cao et al. (1997) reported
possible linkage to 6q21-22 in two independent U.S.
samples: at locus D6S474 using sib-pairPp .00018
analysis in 63 independent sib pairs, and atPp .00095
D6S424 (∼14 cM proximal to D6S474) in a second sam-
ple of 87 independent sib pairs. The same group of re-
searchers reported modest support for linkage to
D6S424 in a third sample consisting of 54 U.S. and
Australian sib pairs; when these researchers combined
samples (141 independent sib pairs), they observed a
nonparametric LOD score of 3.82 ( ) (Mar-Pp .000014
tinez et al. 1999).
Chromosome 8p21-22.—Using a narrow disease def-
inition in a genome scan of 54 U.S. pedigrees, Blouin et
al. (1998) observed a nonparametric LOD score of 3.64
( ) at D8S1771. They obtained additional sup-Pp .0001
port from a dominant-model analysis (dominant het-
erogeneity LOD score of 4.54, assuming 70% of the
families are linked) and from a follow-up sample of 51
pedigrees. When a broad disease definition was used in
this sample, support for linkage increased, yielding a
nonparametric LOD score of 6.17 ( ) (Pul-Pp .0000008
ver et al. 2000). Previously, Pulver et al. (1995) published
preliminary evidence of linkage to this region. Some ad-
ditional support came from Kendler et al. (1996), who
found a maximum LOD score of 2.34, using a dominant
genetic model and a broad disease definition, in 265 Irish
pedigrees. Further support for linkage to 8p21 was re-
ported by Brzustowicz et al. (1999), with a maximum
LOD score of 3.49 at marker D8S136, under a dominant
model and narrow disease phenotype, in 21 Canadian
families.
Chromosome 9q21-22.—In their Finnish study (see
the “Chromosome 1q32-41” subsection, above), Hov-
atta et al. (1999) also observed a maximum LOD score
of 1.95 at marker D9S922, under a dominant model.
Other investigators (Moises et al. 1995; Levinson et al.
1998) reported some support for linkage to this region,
although at marginal statistical significance.
Chromosome 10p11-15.—Faraone et al. (1998) re-
ported a genome scan of 43 U.S. nuclear families, with
suggestive linkage in 50 independent sib pairs using a
narrow disease definition. The nonparametric LOD
scores at markers D10S1423 and D10S582 were 3.4
( ) and 3.2 ( ), respectively. Suppor-Pp .0004 Pp .0006
tive evidence was provided by Schwab et al. (1998a),
with a nonparametric LOD score of 3.2 ( ) atPp .0007
marker D10S1714, in 72 German and Israeli families.
Straub et al. (1998) observed a multipoint heterogeneity
LOD score of 1.91 ( ) at with markersPp .006
D10S1426 and D10S674 in 265 Irish pedigrees.
Chromosome 13q14-32.—Blouin et al. (1998) re-
ported a nonparametric LOD score of 4.18 (Pp
), near D13S174 on 13q32, using a narrow dis-.00002
ease phenotype in a genome scan of 54 U.S. pedigrees.
The maximum heterogeneity LOD score for this region,
under a dominant genetic model, was 4.5. This finding
was supported in a follow-up sample of 51 families, with
a nonparametric LOD score of 2.36 ( ) atPp .007
D13S779, ∼7 cM distal to the peak obtained in the first
sample. Further support for this finding was furnished
by Brzustowicz et al. (1999), with a maximum hetero-
geneity LOD score of 4.42 at D13S793 (∼10 cM distal
to D13S779), under a recessive model and a broad dis-
ease definition, in 21 Canadian pedigrees. Other work
(Lin et al. 1997; Shaw et al. 1998) also supported this
finding, although at lower significance levels.
Chromosome 15q13-15.—Stober et al. (2000) re-
ported linkage to 15q15 in a genome scan of 12 German
pedigrees, segregating the periodic catatonia subtype of
schizophrenia. They found a nonparametric LOD score
of 3.57 ( ) and a maximum LOD score ofPp .000026
2.75 at marker D15S1012, under a dominant model.
Marginal support for linkage to15q13-15 in U.S. schizo-
phrenia pedigrees was suggested by Coon et al. (1994b)
and Leonard et al. (1998). The 15q-candidate region
overlaps with a putative schizophrenia locus defined by
a neurophysiological impairment in the P50 auditory
sensory gating (Freedman et al. 1997). It also contains
the a7 nicotinic acetylcholine receptor gene (CHRNA7),
a potential candidate gene.
Chromosome 22q11-13.—Pulver et al. (1994a) ob-
served a maximum LOD score of 2.82 at marker locus
IL2RB, in 39 U.S. pedigrees. Affected sib-pair analysis
in an expanded sample of 57 U.S. pedigrees was con-
sistent with linkage to the same general region (Pp
) (Lasseter et al. 1995). Other investigators (Poly-.009
meropoulos et al. 1994; Coon et al. 1994a; Stober et al.
2000) also reported modest support for linkage. The
implicated region is near the velocardiofacial syndrome
(VCFS) deletion, which is reportedly associated with
psychotic features (see the “Chromosomal aberrations”
subsection, below). It also harbors a putative candidate
gene, which may influence two neurophysiological func-
tions, P50 auditory sensory gating and antisaccade oc-
ular motor performance (Myles-Worsley et al. 1999).
Chromosome Xp11.—This region is of interest, be-
cause it harbors the monoamine oxidase B (MAOB)
gene, a potential candidate gene for neuropsychiatric
disease. The Finnish isolate study (Hovatta et al. 1999;
see the “Chromosome 1q32-41” subsection, above) re-
ported a maximum LOD score of 2.01 at the MAOB
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locus, using a recessive model and a narrow disease def-
inition. Earlier reports found positive LOD scores in the
close vicinity of MAOB, at marker DXS7 (DeLisi et al.
1994a; Dann et al. 1997).
Candidate Genes and Chromosomal Aberrations
In contrast to most linkage studies (which typically
involve genomewide searches), studies of candidate
genes and chromosomal aberrations target specific ge-
nomic sites.
Candidate genes.—Candidate genes for schizophrenia
(genes that encode products with neurobiological func-
tion such as neurotransmitter receptors or enzymes) are
commonly studied by way of association studies.
Whereas linkage analysis tests for cosegregation of a
gene marker and disease phenotype in families, associ-
ation studies examine the co-occurrence of a marker and
disease at the population level, using a case-control de-
sign (unrelated cases and population-based controls).
Family-based controls can also be studied using a trio
consisting of an affected child (case) and two parents
(controls).
Most association studies have focused on genes in-
volved in dopaminergic or serotonergic neurotransmis-
sion. Disturbances in dopaminergic or serotonergic sys-
tems have long been implicated in the pathogenesis of
schizophrenia, primarily because of their role as sites for
antipsychotic drug action. Numerous association studies
have been reported, with conflicting results. Because as-
sociation studies are largely concerned with genes of mi-
nor effect, studies of large, statistically powerful samples
may produce more compelling results than the more typ-
ical small-scale studies have done. Two such studies,
which aimed to pursue previously reported suggestive
results, warrant attention and are described below.
Spurlock et al. (1998) examined polymorphisms in the
dopamine DRD2 and DRD3 receptor genes in a large
European multicenter sample. They studied two poly-
morphisms: Ser311Cys (in exon 7 of DRD2) and Ser9gly
(in exon 1 of DRD3) in samples of 373 and 413, and
311 and 306 patients and controls, respectively. They
found no evidence of allelic association with the DRD2
polymorphism and no homozygotes for this variant.
However, an excess of homozygotes for both alleles of
the DRD3 polymorphism was noted in the patient group
( ), as well as a significant excess of the 1:1Pp .003
(Ser9Ser) genotype ( ), with no allelic associa-Pp .004
tion. They concluded that an association exists between
increased homozygosity of the DRD3 variant and the
disease.
Williams et al. (1996) studied the serotonin poly-
morphism T102C of the gene for 5-hydroxytryptamine
type 2a (5-H2Ta) receptor, in a large European multi-
center sample of 571 patients and 631 matched controls.
They observed significant association between the dis-
ease and allele 2 ( ), as well as a significantPp .003
excess of the½:½ genotype in patients ( ). TheyPp .008
concluded that the 5-HT2a receptor gene—or a locus in
linkage disequilibrium with it—confers susceptibility to
schizophrenia.
Association studies with specific genes that may be
involved in genetic anticipation (progressively earlier age
at onset or increased severity in successive generations)
have also been of interest (1) because these genes, which
are characterized by trinucleotide repeat expansions, are
common in human brain, and (2) because anticipation
has been reported in schizophrenia. However, the search
for such genes has yielded conflicting results, with no
evidence for a clear-cut relationship between the tri-
nucleotide-repeat size and age at onset of the disease
(Sasaki et al. 1996; Morris et al. 1995; O’Donovan et
al. 1995). Also, the evidence for anticipation in schizo-
phrenia may be fraught with ascertainment bias (Ash-
erson et al. 1994).
Chromosomal aberrations.—Chromosomal aberra-
tions have been instrumental in identifying disease genes.
There are numerous accounts of associations between
schizophrenia and chromosomal aberrations, including
the partial trisomy of 5q11-13 (Bassett et al. 1988)
which led to the claimed linkage to DNA markers in
this region (see the “Linkage Studies” subsection,
above). In a separate publication, Bassett (1992) re-
viewed earlier reports. Later accounts include trans-
locations such as t(2;18)(p11.2;p11.2) (Maziade et al.
1993) and t(1;7)(p22;q22) (Gordon et al. 1994), inver-
sions such as 9p11-9q13 (Nanko et al. 1993) and
4p15.2-q21.3 (Palmour et al. 1994), trisomies of 5p14.1
(Malaspina et al. 1992) and 8 (Ong and Robertson
1995), fragile sites at 8q24 and 10q24 (Garofalo et al.
1993), deletions at 22q11.1 (Karayiorgou et al. 1995)
and 5q21-23.1 (Bennett et al. 1997), and sex aneuplo-
idies (reviewed in DeLisi et al. 1994b).
Because of the high prevalence of schizophrenia, and
the fact that most of the reported chromosomal aber-
rations are confined to isolated cases, it is likely that the
great majority of these associations are spurious. Con-
fidence in the potential relevance of a particular finding
can be enhanced by (1) increasing the rate of the chro-
mosomal anomaly in the patient population, (2) increas-
ing the rate of the disease among patients with the chro-
mosomal anomaly, or (3) finding independent evidence
of linkage between the disease and the specific genomic
region. One of the reported aberrations—the deletion at
22q11, which overlaps the region involved in VCFS
(Karayiorgou et al. 1995; also see the “Linkage Studies”
subsection, above)—appears to meet these criteria and
warrants further study.
Baron: Genetics of Schizophrenia 303
Methodological Issues
Although some of the aforementioned results show
promise, the failure of attempts to replicate results and
the limited power to detect and replicate gene effects, as
well as limited power to distinguish true-positive results
from false-positive ones, continue to mar the search for
susceptibility genes in schizophrenia.Methodological re-
finements that may expedite this search involve new per-
spectives on phenotype definition and new analytical
approaches.
The Phenotype
The lack of external validating criteria and the con-
siderable variability in clinical manifestations present a
challenge to genetic studies. Strategies that attempt to
redress this problem include (1) dissecting the phenotype
to clinical subtypes that cluster in families and that may
have distinct underlying genetic bases and (2) supplant-
ing discrete phenotypes by quantitative measures, such
as symptom-based algorithms and biological endo-
phenotypes, that may be more closely related to the un-
derlying genetic vulnerability. The use of quantitative
measures may also provide a greater power to detect
linkage than the power provided by use of discrete phe-
notypes. Another strategy to overcome the challenges of
genetic studies is to blur the diagnostic boundaries be-
tween schizophrenia and other major psychiatric dis-
orders, such as bipolar disorder, to examine genetic com-
monality. Several investigators have recently applied
these strategies, with varying degrees of success.
Clinical Subtypes
As mentioned (see the “Linkage Studies” subsection,
above), Stober et al. (2000) found evidence for a major
locus for the periodic catatonia subtype of schizophrenia
on chromosome15q15. Elsewhere they reported high fa-
milial aggregation of this syndrome, with an estimated
prevalence of 0.1% in the general population (Stober et
al. 1995). Their finding suggests that periodic catatonia
is a genetically homogeneous subtype of schizophrenia
that is linked to a major locus on 15q15.
It should be noted, however, that catatonic schizo-
phrenia is uncommon and that other recent attempts to
determine whether schizophrenia subtypes cluster in
families produced negative results (Leboyer et al. 1992;
Kendler et al. 1994). This suggests that the finding re-
ported by Stober et al. (2000), although potentially rel-
evant for a subset of schizophrenia, may not have general
applicability.
Symptom-Based Analysis
Brzustowicz et al. (1997) studied quantitative clinical
traits, using positive-symptom (psychotic), negative-
symptom (deficit), and general-psychopathology-symp-
tom scales for schizophrenia. Using categorical pheno-
types, they found evidence of linkage between the
positive-symptom trait and marker D6S1960 (Pp
) on chromosome 6p11-21, slightly proximal.0000054
to the 6p21-24 region previously implicated in schizo-
phrenia (see the “Linkage Studies” subsection, above).
The somewhat different localization may result from dif-
ferences in phenotypic classification and marker cover-
age or from the presence of two distinct susceptibility
loci. Interestingly, there was no evidence of linkage when
categorical diagnoses were used. This supports the no-
tions that (1) the use of a quantitative trait may, indeed,
have increased the power to detect linkage and (2) pos-
itive symptoms show more pronounced correlation with
genetic vulnerability at the 6p putative locus.
A different symptom-based approach was taken by
Kendler et al. (2000), who tested for linkage of symptom
and outcome variables to chromosomes 5q21-31, 6p22-
24, 8p21-22, and 10p11-15, all of which are regions
implicated in previous linkage studies using discrete di-
agnoses (see the “Linkage Studies” subsection, above).
There was no evidence of linkage to 5q, 6p, or 10p, but
affected individuals from families with prior evidence of
linkage to 8p21-22 had more affective deterioration,
more thought disorder, fewer depressive symptoms, and
poorer outcome than did affected individuals from other
families. These clinical features are characteristic of the
core, poor-outcome form of schizophrenia. Notwith-
standing methodological limitations (Kendler et al.
2000), the study suggests that a locus on 8p21-22 con-
fers susceptibility to this syndrome.
Biological Endophenotypes
Much attention has focused on two neurobiological
dysfunctions associated with familial schizophrenia: im-
paired gating of the auditory evoked response (Judd et
al. 1992; Freedman et al. 1997) and ocular motor dys-
functions (Holzman et al. 1988; Levy et al. 1993). Im-
paired sensory gating, commonly measured by recording
the P50 wave of the auditory evoked response, reflects
a dysfunction in the brain’s processing of sensory stimuli.
Ocular motor dysfunctions include impaired smooth-
pursuit eye movement and deficient antisaccade ocular
motor performance. The P50 auditory sensory gating
and antisaccade ocular performance are specific mea-
sures of inhibitory neurophysiological functioning. Phys-
iological deficits in these measures occur in most schi-
zophrenics and in many of their unaffected relatives, an
observation consistent with the hypothesis that vulner-
ability to the disease is inherited.
Both putative endophenotypes were tested for linkage
to schizophrenia (see the “Linkage Studies” subsection,
above). Freedman et al. (1997) reported linkage of the
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P50 sensory gating deficit to chromosome 15q13-14, the
site of the a7-nicotinic receptor locus, in nine U.S.
schizophrenia pedigrees (LOD score of 5.3, using a dom-
inant model). Their neurobiological studies suggest that
decreased function of the a7-nicotinic receptor could
underlie the P50 sensory gating defect, a finding that
suggests this gene may have a role in the pathophysiol-
ogy of schizophrenia. In a follow-up study of eight of
these families, Myles-Worsley et al. (1999) reported link-
age between a composite biological phenotype— com-
bining the P50 sensory gating and antisaccade ocular
motor performance—and marker D22S315 on chro-
mosome 22q11-12 (LOD of 3.55, using a dominant
model). This composite endophenotype appeared to
identify nearly 80% of nonschizophrenic relatives as ab-
normal in at least one inhibitory processing domain.
It must be emphasized, however, that the evidence of
linkage between the clinical phenotype and the two chro-
mosomal regions, in this sample and in samples reported
by others (see the “Linkage Studies” subsection, above),
is less pronounced than the linkage reported for the en-
dophenotypes. Also, the endophenotypes appeared to be
governed by dominant major genes, a genetic model un-
likely for schizophrenia generally.
Diagnostic Boundaries
Ordinarily, the disease phenotype can range from
schizophrenia proper (a narrow definition) to broader
phenotype definitions that include what are known as
“spectrum” disorders (disease states that aggregate in
families of schizophrenic patients but do not meet the
criteria for schizophrenia). However, recent data suggest
a broader perspective on this matter. Specifically, al-
though schizophrenia and bipolar affective disorder do
not show significant coaggregation in families and are
generally considered distinct nosological entities, there
is evidence for some overlap (Baron et al. 1982; Gershon
et al. 1988; Maier et al. 1993). In particular, famil-
ies both of schizophrenic and of bipolar patients are at
increased risk for schizoaffective disorder (a syndrome
combining schizophrenic and affective features) and uni-
polar depression. Also, relatives of schizoaffective pa-
tients show increased rates of schizophrenia, bipolar ill-
ness, and unipolar depression. There is, additionally,
some resemblance in epidemiological and clinical fea-
tures: the two disorders have similar prevalence and age
at onset, show no gender preference, are lifelong con-
ditions, and have some common psychotic features.
The apparent partial overlap of schizophrenia and bi-
polar disorder has drawn attention to the notion of
shared susceptibility loci. Indeed, examination of recent
linkage studies shows several chromosomal regions that
are implicated in both disorders. In particular, 1q32,
10p11-15, 13q32, and 22q11-13, which were linked to
schizophrenia in some studies (see the “Linkage Studies”
subsection, above), have also been implicated in bipolar
disorder. For example, Detera-Wadleigh et al. (1999) ob-
served evidence of linkage at 1q32 (LOD score of 2.67;
), 13q32 (LOD score of 3.5; ),Pp .00022 Pp .000028
and 22q11-13 (LOD score of 2.1; ) in 22Pp .00094
U.S. pedigrees with bipolar illness. Foroud et al. (2000)
reported a LOD score of 2.5 ( ) at 10p14, inPp .001
97 U.S. pedigrees with bipolar illness. Another region
of potential interest is 18p11, where Schwab et al.
(1998b) reported modest evidence of linkage to schizo-
phrenia (LOD score of 1.76 at marker D18S53) in 59
German and Israeli families. The LOD score increased
to 3.1 when the phenotype definition was broadened to
include bipolar disorder and unipolar depression. Pos-
sible linkage of bipolar disorder to 18p11 was reported
in an independent sample of 22 U.S. pedigrees (Berrettini
et al. 1994), although the status of this linkage is unclear
(Baron and Knowles 2000). Evidence of shared genetic
susceptibility between schizophrenia and affective dis-
orders may provide cross-validation of genetic findings
and a rationale for some latitude in phenotype definition.
Analytical Approaches
There is an ongoing debate as to the optimal study
design and analytical methods for complex traits such
as schizophrenia. Issues that warrant attention include
linkage and association methods, meta-analyses, and
novel analytical models.
Linkage Methods
Linkage analysis examines familial cosegregation of a
gene marker and a disease phenotype, to determine
whether the marker and the disease are physically linked.
Controversial issues include sample configuration (sib
pairs in nuclear families vs. extended high-density ped-
igrees), type of analysis (model-free [nonparametric]
methods, e.g., sib-pair analysis, vs. model-based [para-
metric] methods, e.g., LOD scores in pedigrees), and
definition of significant findings.
The advantages and disadvantages of various sample
configurations and types of analysis have been discussed
elsewhere (Vieland et al. 1992; Greenberg et al. 1997
and 1998; Goldgar and Easton 1997; Kruglyak 1997;
Terwilliger 1998; Ott and Hoh 2000) and can be sum-
marized as follows:
Sample configuration.—Proponents of the sib-pair ap-
proach argue that extended pedigrees may be error-
prone for two main reasons: (1) reduced power for link-
age detection may result from intrafamilial heterogeneity
caused by “extraneous” genes entering the pedigree
through marrying-in spouses and (2) selection bias in
favor of a particular form of familial disease with a
dominantlike, single-gene effect may accompany a fail-
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ure to consider more representative mechanisms for
complex traits, such as oligogenic inheritance and mul-
tiple genes of modest effect. It may be argued, however,
that (1) extended pedigrees can be divided into com-
ponent nuclear families to account for intrafamilial het-
erogeneity; (2) sib pairs in small families are also sus-
ceptible to intrafamilial heterogeneity (phenocopies may
be more common because of low illness density); (3)
extended pedigrees contain more genetic information
than small families do, and this results in increased sta-
tistical power, especially when heterogeneity is ac-
counted for; and (4) although the dominantlike appear-
ance of some extended pedigrees may favor the detection
of rarer, large-effect genes, such genes can be more easily
traceable, and their biological impact may be greater
than that of genes of minor effect.
Type of analysis.—Advocates of model-free methods
argue that these methods are more suitable for complex
disorders whose mode of inheritance is uncertain, be-
cause such methods make no assumptions about the un-
derlying genetic transmission. It may be argued, how-
ever, that (1) model-based LOD score analysis has
greater power and is largely robust to model misspeci-
fication, if more than one model is tested; (2) withmodel-
based methods, several different models can be used,
covering a range of genetic hypotheses with adequate
power and with little risk of missing a true linkage; (3)
there is no systematic evidence that model-free methods
have a greater sensitivity for linkage detection than do
model-based methods.
Clearly, there is no one correct method for linkage
detection. The studies reviewed in this article (see the
“Linkage Studies” subsection, above) used a variety of
methods, including nuclear families with sib pairs, ex-
tended pedigrees, and model-free and model-based anal-
ysis. Given the acknowledged complexities, the use of
complementary methods might be advisable, provided
the advantages and disadvantages of the various ap-
proaches are recognized.
Statistical significance.—As mentioned, simulation
studies suggest guidelines for genomewide significance
of linkage results in studies of complex traits (Lander
and Kruglyak 1995). In parametric analysis, the cate-
gories of significant and suggestive linkage correspond
to LOD scores of 3.3 and 1.9, respectively; the corre-
sponding pointwise P values in sib-pair analysis are
.000022 (LOD score of 3.6) and .00074 (LOD score of
2.2). Once significant linkage is observed, a P value of
.01 in an independent study is required for replication.
However, although these guidelines are widely used (see
the “Linkage Studies” subsection, above), debate con-
tinues about what constitutes appropriate thresholds for
significance. What appears to be significant linkage can
be a false-positive result, even in the presence of pre-
sumed replication. Conversely, linkage findings that fall
short may be worth pursuing, especially if contiguous
markers in the candidate region show positive results.
Linkage versus association.—As mentioned, there are
numerous association studies of candidate genes. Al-
though linkage studies continue to play a pivotal role,
association mapping is becoming a competing strategy.
The advantages and disadvantages of linkage and as-
sociation mapping have been widely debated (Crowe
1993; Kidd 1993; Risch and Merikangas 1996; Owen
et al. 1997; Terwilliger and Weiss 1998; Risch 2000;
Weiss and Terwilliger 2000; Ott and Hoh 2000; Baron
1997 and in press). The advantages of association stud-
ies can be summarized as follows: (1) Most of the genetic
variance in complex disease is due to genes of modest
effect. Such genes are probably detectable by association
analysis but may not be amenable to the linkage ap-
proach, which is best suited for genes of larger effect.
(2) The sample-size requirements for linkage detection
are much higher (possibly beyond reach) than those for
association mapping. (3) The slow progress in linkage
mapping of complex disease attests to the constraints of
this approach. (4) The emergent maps of high-density
single-nucleotide polymorphisms (SNPs) should enable
genomewide association studies with tens of thousands
of candidate-SNPs. This may allow systematic assess-
ment of all candidate genes for complex traits such as
psychiatric disease.
There are, however, caveats. First, although linkage
analysis is, indeed, geared toward genes of moderate-to-
large effect, a few examples of common disease alleles
of modest effect have been detected by linkage analysis.
Two examples are apolipoprotein E (ApoE), which pre-
disposes to both a common form of Alzheimer dementia
and to cardiovascular disease, and HLA, which predis-
poses to type I diabetes. Some simulations show that
modest-effect genes (genotypic relative riskp 2) are de-
tectable by linkage analysis with realistic sample sizes
(∼400 sib pairs) (Hauser et al. 1996). Second, enrich-
ment of the sample for disease-allele carriers, by using
clinical subtypes or biological endophenotypes, can aug-
ment the power to detect linkage. Examples of the suc-
cess of this approach include early-onset familial breast
and prostate cancer and, possibly, the aforementioned
linkages to catatonic schizophrenia (15q13-15) and to
the putative schizophrenia endophenotypes P50 (15q13-
15) and the P50-antisaccade composite (22q11-13).
Third, as mentioned (see the “Candidate genes” sub-
section, above), the pattern of conflicting results in as-
sociation studies is at least as pronounced as that in
linkage studies. Also, seemingly significant disease-
marker associations are more likely than not to be spu-
rious, because of the infinitesimally small odds of se-
lecting a likely candidate gene from among themultitude
of genes expressed in human brain. To curtail false-pos-
itive results, the requirements for statistical significance
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would have to be much more stringent, even in samples
substantially larger than those that are deemed feasible.
A further complication arises from spurious results
caused by sample stratification (in case-control designs),
although this can be rectified by using family-based con-
trols. Second, although systematic genome searches with
SNPs can circumvent limitations in current designs that
focus on a few favored candidate genes, there are po-
tential drawbacks. For example, given the vast number
of test results, there are questions concerning the statis-
tical thresholds required to curb false-positive results.
Also, in the presence of substantial allelic heterogeneity,
there may never be enough power for the confident de-
tection of modest gene effects, even with huge popula-
tion samples. There are also questions about the effi-
ciency of SNP mapping. For example, the number of
required markers may have to be severalfold larger (hun-
dreds of thousands, including noncoding SNPs), com-
pounding the effects of multiple testing and augmenting
an already substantial and costly genotyping effort. Also,
a linkage disequilibrium map is needed for the entire
genome, given the high variability across the genome.
Further statistical, computational, and technological
advances are needed to render this approach fully
applicable.
Joint linkage and association.—It may be argued that
a two-stage procedure would be more feasible and cost-
effective than the aforementioned genomewide associ-
ation strategy, namely, initial genome scan using linkage
analysis followed by high-density association (linkage
disequilibrium) mapping with candidate SNPs, only in
target regions identified by the preceding linkage analysis
(Baron in press). For example, pursuant to the initial
accounts of linkage between schizophrenia and chro-
mosome 6p21 (see the “Linkage Studies” subsection,
above), Wei and Hemmings (2000) conducted a linkage
disequilibrium test with densely spaced DNA markers
(including SNPs) in the major histocompatibility com-
plex region, which is mapped to 6p21. They showed
that two haplotypes for the gene NOTCH4, which may
be involved in neurogenesis, are strongly associated with
schizophrenia ( and , re-Pp .0000078 Pp .000011
spectively). Of course, a potential drawback is that genes
of minor effect may elude detection in the initial linkage
stage.
The presence of allelic association can, in turn, aug-
ment the power of linkage analysis to uncover gene ef-
fects that might otherwise remain ambiguous. For ex-
ample, a joint linkage and association test has revealed
evidence for two complex disease genes: a major locus
for psoriasis, on chromosome 6p21 (Trembath et al.
1997), and the type 1 angiotensin II receptor gene related
to essential hypertension (Kainulainen et al. 1999).
Meta-analyses.—Sample-size requirements for linkage
detection in complex traits depend on the underlying
gene effects. For example, a locus with a genotypic rel-
ative risk of 2 may require 400 sib pairs for adequate
power (Hauser et al. 1996), whereas a smaller relative
risk may necessitate much larger samples (Risch and
Merikangas 1996). The samples required for replication
may be larger yet (Suarez et al. 1994). Large samples
may augment weak linkage signals found in small data
sets (if linkage is present) and are less susceptible to
random statistical fluctuations that may lead to false-
positive results in smaller samples. Because samples of
this magnitude are generally not available in single stud-
ies, meta-analyses of multiple independent data sets have
been proposed as an alternative. Several analyses have
been reported that focus on chromosomal regions with
prior evidence of possible linkage.
Gill et al. (1996), following up on a previous, smaller
meta-analysis of chromosome 22q11-13 (Pulver et al.
1994b), analyzed a combined sample of 620 sib pairs
in 574 pedigrees collected by 11 independent research
groups. They focused on marker D22S278 because it
showed the strongest evidence for linkage in three
previous studies. When a narrow disease definition was
used, the combined sib-pair analysis showedmodest sup-
port for excess allele sharing at D22S278 ( orPp .001
, depending on the availability of parentalPp .006
genotypes).
Subsequently, 14 research groups studied 14 markers
on chromosomes 3p, 6p, and 8p in 567 pedigrees, in-
cluding 687 independent sib pairs (Schizophrenia Link-
age Collaborative Group for Chromosomes 3p, 6p, and
8p 1996). There was no evidence for linkage to chro-
mosome 3p. When a narrow diagnostic model was used,
suggestive support for linkage was observed for chro-
mosomes 6p22-24 (sib-pair analysis, for thePp .0004
combined sample, after removing the samplePp .001
in which the first linkage finding was reported) and
8p21-22 (heterogeneity LOD score of 3.06, Pp
for the combined sample, LOD score of 2.22,.00018
with the original sample removed).Pp .0014
Recently, Levinson et al. (2000) analyzed candidate
regions on chromosomes 5q, 6q, 10p, and 13q in 734
pedigrees, including 824 independent sib pairs, collected
by eight research groups. They found modest support
for linkage to chromosome 6q21-22 (a LOD score of
3.10, , sib-pair analysis; nonparametric LODPp .0036
score of 2.47, ; recessive LOD score of 2.47),Pp .0046
with or without the sample in which linkage evidence
was first reported. Weak support for linkage was ob-
served on chromosome 10p11-15, with no evidence for
linkage to chromosomes 5q or 13q.
At face value, these multicenter studies support pre-
viously reported linkage to some chromosomal regions
(6p, 6q, 8p, and 22q), although the evidence is far from
conclusive in spite of the sizable sample. The evidence
in other implicated regions (10p and 13q) is substantially
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weaker than that in the original reports. However, there
are drawbacks that limit the interpretation of results
(Rice et al. 1997). These include differences among sam-
ples—in ascertainment, diagnostic and laboratory meth-
ods, marker density and informativeness, or other fac-
tors—and possible selection bias resulting from (1) the
inclusion of the original positive data sets or (2) the
proclivity of researchers to study more intensively chro-
mosomal regions in which they already have evidence
of linkage or to select these regions prior to others, to
the exclusion of a more systematic study of the genome.
A potential bias of this type may have occurred in the
22q-multicenter study (Gill et al. 1996), which included
the original samples with linkage evidence at marker
D22S278.
Meta-analyses may be useful in guiding the search for
disease genes. However, in most cases, a single sizable
study involving a systematic genomewide search (or a
set of studies with a common design) is preferable to a
post hoc meta-analysis of multiple data sets collected
under various conditions. Several such studies are under
way.
Novel analytical models.—Most current models do
not allow the simultaneous consideration of suscepti-
bility loci from various chromosomal regions. Instead,
they treat separate disease loci as if they were indepen-
dent of each other. As a result, these models may not
have sufficient power to detect the various genes in-
volved in complex disease, in particular genes of small
effect. Recently, new statistical methods have been de-
veloped to address this issue. For example, Cox et al.
(1999) described an approach to assessing statistical in-
teractions between different chromosomal regions
whereby the evidence for linkage at one region is taken
into account in assessing the evidence for linkage else-
where in the genome. Using this approach, they showed
an interaction between loci on chromosomes 2 and 15
that increases susceptibility to non–insulin-dependent
diabetes (NIDD1). Interestingly, conventional linkage
analysis failed to detect linkage to chromosome 15 in
the initial genome scan. Because the genetic complexity
of schizophrenia appears comparable to that of diabetes,
this example is of potential interest. The use of other
novel techniques that involve neural networks is pro-
posed to examine the inheritance of all markers jointly
over the entire genome (Lucek et al. 1998; Hoh and Ott
2000). This approach may uncover interactions among
the multiple genes that underlie complex disorders such
as schizophrenia. Power to detect genes of small effect
can also be increased by methods that analyze multiple
tightly linked markers, an approach that can extract
more information on genetic linkage than is provided
by existing statistical models (Zhao et al. 2000). It may
also be possible to enhance the abilities of linkage and
association analysis to detect genes of small effect by the
combined use of path analysis, segregation analysis, and
linkage/association analysis (Rao and Province 2000).
This method may allow systematic examination of mul-
tiple risk factors, both genetic and nongenetic. Finally,
the recent emergence of technologies based on microar-
rays (DNA chips) may enable an extensive evaluation
of interactions among thousands of genes in the entire
genome, a task that exceeds the capacity of current link-
age and association mapping (Ott and Hoh 2000).
Summary and Outlook
Methodological issues notwisthanding, the available ev-
idence supports multiple candidate regions as possible
sites for schizophrenia-susceptibility genes—in particu-
lar, chromosomes 1q, 4q, 5p, 5q, 6p, 6q, 8p, 9q, 10p,
13q, 15q, 22q, and Xp. However, as with other complex
diseases, not all studies agree.Most of the positive results
are at the suggestive level; and the chromosomal regions
implicated are large, thereby complicating the search for
disease genes. It remains to be seen which, if any, of
these hypothesis-generating findings will result in gene
discovery. The definitive studies have yet to be done. In
particular, (1) the collection of large-scale, well-char-
acterized data sets (including detailed phenotypic infor-
mation and cell lines from extended pedigrees, sib pairs,
simplex families, and population-based case-control
samples) using common, standardized research proto-
cols; (2) marker-intensive genomewide searches for link-
age and association, using the ever-improving genomic
maps and gene catalogue; (3) application of novel tech-
nologies such as DNA pooling, DNA-chip methods, and
high-speed SNP testing, as well as advanced statistical
and biocomputing tools. These approaches are better
suited than hitherto published efforts to the identifica-
tion of genes for schizophrenia and to the improvement
of cost-effectiveness. All the same, existing studies with
promising results need not await the completion of the
more definitive large-scale efforts such as phenotypic re-
finement, application of new statistical tools, and inten-
sive molecular studies of candidate regions may bear
fruit in some cases. It may well be that genes of mod-
erate-to-large effect will be the first to be identified, if
such genes exist. The search for multiple genes of minor
effects will be more painstaking.
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